ORAGENICS INC (OGEN)

Company Profile

Oragenics, Inc. operates as a development-stage company, which engages in research and development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. The company is headquartered in Tampa, Florida and currently employs 6 full-time employees. The company went IPO on 2003-07-09. Its lead product NT-CoV2-1 is an intranasal vaccine candidate to prevent coronavirus disease (COVID-19) from the SARS-CoV-2 virus and variants thereof. Its lantibiotics program features a novel class of antibiotics against bacteria its research has shown may be applicable to multiple antibiotic-resistant organisms. Its Antibiotics product is a semi-synthetic analog of MU1140, which is a member of lantibiotic class of antibiotics. Its product pipeline also includes ONP-002, which is a fully synthetic neurosteroid being developed to treat mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC). Through its wholly owned subsidiary, Noachis Terra, is engaged in the research and development stage for its new Terra CoV-2 and NT-CoV2-1 vaccine product candidates.

Company Info

ORAGENICS INC

Suite 125, 4902 Eisenhower Blvd

Tampa FLORIDA 33634

P: 18132867900

CEO: Alan Joslyn

Employees: 6

Website: https://www.oragenics.com/